The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a ...
Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have ...
The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy.
The health policy think tank urged seniors to shop carefully for prescription drug coverage during Medicare open enrollment, ...
The breakup, which will separate Aetna and Caremark from CVS’ retail pharmacies, is an indictment of the dogma that bigger is always better in the healthcare industry.
AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...
On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall ...
The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.
Explore how integrated scenario modeling helps pharma leaders navigate pricing uncertainty and the complexity of global ...
At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share ...
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...
The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results